Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors

• Status: Active, not recruiting
• Trial end date: 2022-06-01

Summary

The purpose of this study is to learn about the safety and effectiveness of two different drug combinations in patients who have intermediate- and poor-risk germ cell tumors (GCT). One combination of drugs, paclitaxel, ifosfamide and cisplatin (TIP), is experimental. The other combination of drugs, bleomycin, etoposide and cisplatin (BEP), is the standard of care treatment for intermediate- and poor-risk germ cell tumors. However, BEP does not cure every patient and therefore newer treatments are needed.

• Phase: Phase 2

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborators: Mayo Clinic; Stanford University; University of Chicago; University of North Carolina; University of Pittsburgh; University of Southern California; University of Texas Southwestern Medical Center
• Treatments: Albumin-Bound Paclitaxel; Bleomycin; Cisplatin; Etoposide; Etoposide phosphate; Ifosfamide; Isophosphamide mustard; Mesna; Paclitaxel